ReviewBritish journal of cancer2003
Surrogate markers in antiangiogenesis clinical trials.
Review in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 76 citations in OpenAlex.
- A phase I surrogate endpoint study of SU6668 in patients with solid tumors.Investigational new drugs · 2004Trial
- Therapeutic Potential of Curcumin for the Treatment of Brain Tumors.Oxidative medicine and cellular longevity · 2016Review
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.Oncotarget · 2014Article
- Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy.Cancer research · 2014Article
- Angiogenesis in spontaneous tumors and implications for comparative tumor biology.TheScientificWorldJournal · 2014Review
- Use of Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovasculari- zation as well as Tumor Cells in Molecular Tumor Imaging.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2012Article
- Bevacizumab for the treatment of recurrent glioblastoma.Clinical Medicine Insights. Oncology · 2011Article
- Medical imaging in new drug clinical development.Journal of thoracic disease · 2010Article
- A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.Investigational new drugs · 2010Article
- Bevacizumab in the treatment of non-small-cell lung cancer.Oncogene · 2007Review
- Effects of recombinant human canstatin protein in the treatment of pancreatic cancer.World journal of gastroenterology · 2006Article
- Review
- Anti-angiogenic therapy in pediatric neuro-oncology.Journal of neuro-oncology · 2005Review
- Evaluation of tumor angiogenesis with a second-generation US contrast medium in a rat breast tumor model.Korean journal of radiologyArticle
- Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope.Journal of cellular and molecular medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogenesis and the realisation that developing clinically useful antiangiogenic therapy will be more challenging than originally thought. It is now apparent that new methods and surrogate markers to assess these agents' biological activity are crucial for their successful development. This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.